Necrotizing Enterocolitis Clinical Trial
Official title:
Evaluation of the Safety of Fecal Microbiota Transplantation (FMT) as a Prophylaxis of Necrotizing Enterocolitis (NEC) in a Group of Newborns at Increased Risk for the Disease
The aim of the study is to assess the safety of fecal microbiota transplantation (FMT) as a preventive method for the development of Necrotizing enterocolitis (NEC) in a group of premature infants. This is the first stage of a clinical trial testing the effectiveness of FMT in NEC, the aim of which is to examine the safety profile and analyze all side effects.
Status | Not yet recruiting |
Enrollment | 20 |
Est. completion date | January 31, 2025 |
Est. primary completion date | January 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 24 Weeks to 36 Weeks |
Eligibility | Inclusion Criteria: - Preterm infants hospitalized in the intensive care unit and neonatal pathology unit during the study period 1. 1. Born naturally or by cesarean section between: 1. 24 0/7 and 36 6/7 weeks of gestation 2. Age >48 hours, a minimum of 24 hours after completion of antibiotic therapy and up to day 14 for newborns <35 weeks of gestation and up to day 6 for newborns >35 weeks of gestation 3. Newborns born in and out of hospital 4. Parental consent to participate in the study Exclusion Criteria: 1. Occurrence of congenital defects of the gastrointestinal tract preventing proper intestinal passage (esophageal atresia, duodenal atresia, rectal atresia, tracheo-esophageal fistulas) and occurrence of genetic diseases diagnosed prenatally or at birth (trisomies, other genetic syndromes). 2. Gastrointestinal perforation 3. Food allergy with anaphylactic shock 4. Participation in another clinical trial that may affect the final outcome of the planned intervention Temporary exclusion criteria If at least 1 of the following occurs before FMT and up to 14 days of age: 1. Intolerance to oral feeding, based on the assessment of the qualifying physician on the day of FMT: - painful bloating in the abdomen and/or visible bowel loops, blood in the stools, - delayed gastric emptying: two consecutive episodes exceeding >50% of the volume of the previous serving, 2 or more consecutive episodes of retention / vomiting / regurgitation of biliary contents / duodenal contents/ blood - episodes not related to anxiety, delayed bowel movements, possibility of swallowing blood during childbirth or from damaged nipples, abnormality of the positioning of gastric tube, bleeding from the nose 2. Suspected NEC: - clinical signs typical for NEC - Bell criteria, redness/bruising of the anterior abdominal wall, palpable abdominal resistance, hypotension; laboratory signs: hyponatraemia, metabolic acidosis, thrombocytopenia, increased inflammation parameters) 3. Antibiotic therapy during planned FMT treatment 4. Clinical signs of infection or significantly elevated inflammatory parameters - If at least one of the following clinical signs and/or more than 1 laboratory sign occurs: • Clinical signs of infection: Hemodynamic instability (hypotension, tachycardia, peripheral circulatory disturbances (by age standards), thermoregulatory disturbances, fever>38 deg C, hypothermia <36 deg C) Apathy, lethargy, convulsions Apneas, deterioration of respiratory capacity • Labolatory signs of infection: Elevated inflammatory parameters: - leukocytosis <5 i >30x109/L up to 48 hours of life (HoL) and <5 i >20x109/L >48 hours of life, the band neutrophil : total neutrophil (I:T) ratio of >0.2 for >34 weeks of gestation and >0,16 for <34 weeks of gestation - CRP >0.05mg/l (at the norm up to <0.05-1mg/l), - PCT (>72 HoL) > 0,5-1ng/ml (at the norm up to > 0,5-1ng/ml); Platelet count < 50K, coagulopathy positive cultures of normally sterile body fluids - Radiological evidence of infection, including systemic e. g. gallbladder bed swelling, unexplained sudden echocardiographic pulmonary hypertension |
Country | Name | City | State |
---|---|---|---|
Poland | Medical University of Warsaw, Pediatric Surgery Clinic | Warsaw | Mazovian Voivodeship |
Lead Sponsor | Collaborator |
---|---|
Medical University of Warsaw |
Poland,
Hui Y, Vestergaard G, Deng L, Kot WP, Thymann T, Brunse A, Nielsen DS. Donor-dependent fecal microbiota transplantation efficacy against necrotizing enterocolitis in preterm pigs. NPJ Biofilms Microbiomes. 2022 Jun 9;8(1):48. doi: 10.1038/s41522-022-00310-2. — View Citation
Korpela K, Helve O, Kolho KL, Saisto T, Skogberg K, Dikareva E, Stefanovic V, Salonen A, Andersson S, de Vos WM. Maternal Fecal Microbiota Transplantation in Cesarean-Born Infants Rapidly Restores Normal Gut Microbial Development: A Proof-of-Concept Study. Cell. 2020 Oct 15;183(2):324-334.e5. doi: 10.1016/j.cell.2020.08.047. Epub 2020 Oct 1. — View Citation
Li X, Li X, Shang Q, Gao Z, Hao F, Guo H, Guo C. Fecal microbiota transplantation (FMT) could reverse the severity of experimental necrotizing enterocolitis (NEC) via oxidative stress modulation. Free Radic Biol Med. 2017 Jul;108:32-43. doi: 10.1016/j.freeradbiomed.2017.03.011. Epub 2017 Mar 16. — View Citation
Liu J, Miyake H, Zhu H, Li B, Alganabi M, Lee C, Pierro A. Fecal microbiota transplantation by enema reduces intestinal injury in experimental necrotizing enterocolitis. J Pediatr Surg. 2020 Jun;55(6):1094-1098. doi: 10.1016/j.jpedsurg.2020.02.035. Epub 2020 Feb 26. — View Citation
Ma X, Xu T, Qian M, Zhang Y, Yang Z, Han X. Faecal microbiota transplantation alleviates early-life antibiotic-induced gut microbiota dysbiosis and mucosa injuries in a neonatal piglet model. Microbiol Res. 2021 Dec 10;255:126942. doi: 10.1016/j.micres.2021.126942. Online ahead of print. — View Citation
Prado C, Michels M, Avila P, Burger H, Milioli MVM, Dal-Pizzol F. The protective effects of fecal microbiota transplantation in an experimental model of necrotizing enterocolitis. J Pediatr Surg. 2019 Aug;54(8):1578-1583. doi: 10.1016/j.jpedsurg.2018.10.045. Epub 2018 Oct 22. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Adverse reactions monitoring | The safety of the procedure will be assessed on the basis of:
number of episodes of oral feeding intolerance, diarrhoea, blood/mucus/pus in stools appearance of symptoms of infection or significant change in vital parameters (heart rate ECG and oxygen saturation - continuous measurement, blood pressure 4x/day, temperature, possibly HERO) number of developed NEC assessment of blood flow in the upper mesenteric artery by ultrasound observation of other symptoms - convulsions, unbridled crying, anxiety the number of positive blood cultures, the percentage of antibiotic therapy number of serious side effects - death, serious threat to health and/or life and/or deterioration of health Length of hospitalization |
Up to the discharge from the hospital (approximately from 2 weeks to 3 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05544097 -
Spectral Analysis of Bowel Sounds in Preterm Babies of Less Than 32 Weeks of Amenorrhea (WA) as Predictive Factor of Enterocolitis
|
N/A | |
Recruiting |
NCT03210831 -
Early Predictors of Necrotizing Enterocolitis in Neonates
|
||
Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
Recruiting |
NCT02552706 -
The Efficacy and Mechanisms of Oral Probiotics in Preventing Necrotizing Enterocolitis
|
N/A | |
Completed |
NCT02400697 -
Placental Transfusion Project for Preterm Infants
|
N/A | |
Completed |
NCT01751477 -
Infloran® for Prevention of Necrotizing Enterocolitis
|
N/A | |
Terminated |
NCT01156480 -
Anti-inflammatory Treatment at the Onset of Necrotizing Enterocolitis (NEC) in Preterm Infants
|
N/A | |
Completed |
NCT00787124 -
Transfusions and Nitric Oxide Level in Preterm Infants
|
||
Unknown status |
NCT00254176 -
Cysteine Supplementation in Critically Ill Neonates
|
Phase 2/Phase 3 | |
Recruiting |
NCT01441739 -
Intestinal Failure in Necrotising Enterocolitis
|
N/A | |
Recruiting |
NCT04074824 -
A Genome-Wide Association Study for Neonatal Diseases
|
||
Recruiting |
NCT03869827 -
Necrotizing Enterocolitis in Fetuses With Intrauterine Growth Restriction
|
||
Terminated |
NCT03320785 -
Circulating Markers in Preterm Infants With Perinatal and Neonatal Inflammation
|
||
Active, not recruiting |
NCT03554278 -
Alteration of Stool Microbiota in Preterm Infants With Anemia
|
||
Not yet recruiting |
NCT04541771 -
The Role of Lactobacillus Reuteri in Preventing Necrotizing Enterocolitis (NEC) in Pre-term Infants
|
Phase 2 | |
Not yet recruiting |
NCT03700957 -
The Impact of Docosahexaenoic Acid on the Prevention of Necrotizing Enterocolitis in Preterm Neonates
|
N/A | |
Completed |
NCT03551600 -
Splanchnic and Renal Tissue Oxygenation During Enteral Feedings in Neonates With Patent Ductus Arteriosus
|
||
Completed |
NCT01745510 -
Enteral Administration of Docosahexaenoic Acid to Prevent Necrotizing Enterocolitis in Preterm Neonates
|
Phase 1/Phase 2 | |
Unknown status |
NCT01807858 -
The Effects of Synbiotics on Morbidity and Mortality in Preterm Infants
|
N/A | |
Completed |
NCT01735578 -
Splanchnic Tissue Oxygenation During Enteral Feedings in Anemic Premature Infants at Risk for Necrotizing Enterocolitis
|
N/A |